26 January 2012 Oryzon to Present at 4th CHI X-Gen Congress, Epigenetics, Targets and Therapies on March 6
6 February 2012 Oryzon nominates bispecific LSD1/MAOB inhibitor as drug candidate to enter preclinical development in Huntington´s Disease
8 May 2012 Oryzon to Present its LSD1 program in Acute Leukemias at the GTC’s 2nd Epigenetics in Drug Discovery conference in Boston
25 May 2012 Oryzon nominates specific LSD1 inhibitor as drug candidate to enter preclinical development in Acute leukemia and other hematological cancers
13 June 2012 Oryzon assigns Dr. Xavier Luria as Non-Executive Director of Medical and Regulatory Affairs